title: Deferasirox for managing iron overload in people with myelodysplastic syndrome.
abstract: BACKGROUND
  The myelodysplastic syndrome (MDS) comprises a diverse group of haematopoietic stem cell disorders. Due to symptomatic anaemia, most people with MDS require supportive therapy including repeated red blood cell (RBC) transfusions. In combination with increased iron absorption, this contributes to the accumulation of iron resulting in secondary iron overload and the risk of organ dysfunction and reduced life expectancy. Since the human body has no natural means of removing excess iron, iron chelation therapy, i.e. the pharmacological treatment of iron overload, is usually recommended. However, it is unclear whether or not the newer oral chelator deferasirox leads to relevant benefit.
  
  
  OBJECTIVE
  To evaluate the effectiveness and safety of oral deferasirox for managing iron overload in people with myelodysplastic syndrome (MDS).
  
  
  METHODS
  We searched the following databases up to 03 April 2014: MEDLINE, EMBASE, The Cochrane Library, Biosis Previews, Web of Science, Derwent Drug File and four trial registries: Current Controlled Trials (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), ICTRP (www.who.int./ictrp/en/), and German Clinical Trial Register (www.drks.de).
  
  
  METHODS
  Randomised controlled trials (RCTs) comparing deferasirox with no therapy, placebo or with another iron-chelating treatment schedule.
  
  
  METHODS
  We did not identify any trials eligible for inclusion in this review.
  
  
  RESULTS
  No trials met our inclusion criteria. However, we identified three ongoing and one completed trial (published as an abstract only and in insufficient detail to permit us to decide on inclusion) comparing deferasirox with deferoxamine, placebo or no treatment.
  
  
  CONCLUSIONS
  We planned to report evidence from RCTs that evaluated the effectiveness of deferasirox compared to either placebo, no treatment or other chelating regimens, such as deferoxamine, in people with MDS. However, we did not identify any completed RCTs addressing this question.We found three ongoing and one completed RCT (published as an abstract only and in insufficient detail) comparing deferasirox with deferoxamine, placebo or no treatment and data will hopefully be available soon. These results will be important to inform physicians and patients on the advantages and disadvantages of this treatment option.
authors.affiliation: German Cochrane Centre, Medical Center - University of Freiburg, Berliner Allee 29, Freiburg, Germany, 79110.
authors.forename: Joerg J
authors.initials: JJ
authors.lastname: Meerpohl
authors.forename: Lisa K
authors.initials: LK
authors.lastname: Schell
authors.forename: Gerta
authors.initials: G
authors.lastname: Rücker
authors.forename: Nigel
authors.initials: N
authors.lastname: Fleeman
authors.forename: Edith
authors.initials: E
authors.lastname: Motschall
authors.forename: Charlotte M
authors.initials: CM
authors.lastname: Niemeyer
authors.forename: Dirk
authors.initials: D
authors.lastname: Bassler
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D015913:Chelation Therapy / Q000379:methods*; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000150:complications*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox